WO2010031248A8 - 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途 - Google Patents

噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途 Download PDF

Info

Publication number
WO2010031248A8
WO2010031248A8 PCT/CN2009/001036 CN2009001036W WO2010031248A8 WO 2010031248 A8 WO2010031248 A8 WO 2010031248A8 CN 2009001036 W CN2009001036 W CN 2009001036W WO 2010031248 A8 WO2010031248 A8 WO 2010031248A8
Authority
WO
WIPO (PCT)
Prior art keywords
treating
salt compound
thiazolium salt
protein
protein aging
Prior art date
Application number
PCT/CN2009/001036
Other languages
English (en)
French (fr)
Other versions
WO2010031248A1 (zh
Inventor
李松
钟武
王莉莉
郑志兵
崔浩
肖军海
程罡
谢云德
张冰
Original Assignee
北京摩力克科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京摩力克科技有限公司 filed Critical 北京摩力克科技有限公司
Priority to US13/120,009 priority Critical patent/US8338616B2/en
Priority to EP09813969A priority patent/EP2341048B1/en
Priority to JP2011527183A priority patent/JP6050586B2/ja
Publication of WO2010031248A1 publication Critical patent/WO2010031248A1/zh
Publication of WO2010031248A8 publication Critical patent/WO2010031248A8/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PCT/CN2009/001036 2008-09-22 2009-09-15 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途 WO2010031248A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/120,009 US8338616B2 (en) 2008-09-22 2009-09-15 Thiazoliums and their use for treating protein aging associated diseases
EP09813969A EP2341048B1 (en) 2008-09-22 2009-09-15 Thiazolium salt compound and its use for treating protein aging associated diseases
JP2011527183A JP6050586B2 (ja) 2008-09-22 2009-09-15 チアゾリウム塩化合物及びタンパク質老化疾患を治療する用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2008102116577A CN101684106B (zh) 2008-09-22 2008-09-22 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
CN200810211657.7 2008-09-22

Publications (2)

Publication Number Publication Date
WO2010031248A1 WO2010031248A1 (zh) 2010-03-25
WO2010031248A8 true WO2010031248A8 (zh) 2011-05-05

Family

ID=42039079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/001036 WO2010031248A1 (zh) 2008-09-22 2009-09-15 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途

Country Status (6)

Country Link
US (1) US8338616B2 (zh)
EP (1) EP2341048B1 (zh)
JP (1) JP6050586B2 (zh)
CN (1) CN101684106B (zh)
HK (1) HK1142607A1 (zh)
WO (1) WO2010031248A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015014682A2 (pt) 2012-12-20 2017-07-11 Colgate Palmolive Co composição para a higiene bucal contendo líquidos iônicos
US20150335548A1 (en) * 2012-12-20 2015-11-26 Colgate-Palmolive Company Oral Care Composition
CN104277011A (zh) 2013-07-09 2015-01-14 中国人民解放军军事医学科学院毒物药物研究所 噻唑内盐类化合物及其治疗蛋白老化相关疾病的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185334A (en) * 1989-07-31 1993-02-09 Schering Corporation 2,2-disubstituted glycerol and glycerol-like compounds, compositions and methods of use
MX9705449A (es) * 1995-01-18 1998-02-28 Alteon Inc Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada.
WO2002062301A2 (en) * 2001-02-07 2002-08-15 Farrington Pharmaceuticals, Llc Method and composition for rejuvinating cells, tissues, organs, hair and nails
MY156407A (en) * 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
CN100349881C (zh) 2003-04-02 2007-11-21 深圳市东阳光实业发展有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
CN101007789B (zh) * 2006-01-27 2014-08-20 北京摩力克科技有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途

Also Published As

Publication number Publication date
HK1142607A1 (en) 2010-12-10
EP2341048B1 (en) 2013-03-06
WO2010031248A1 (zh) 2010-03-25
EP2341048A4 (en) 2012-02-29
EP2341048A1 (en) 2011-07-06
US20110178141A1 (en) 2011-07-21
CN101684106A (zh) 2010-03-31
JP2012502929A (ja) 2012-02-02
JP6050586B2 (ja) 2016-12-21
CN101684106B (zh) 2013-06-12
US8338616B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
WO2010001169A3 (en) Chemical compounds 251
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
TR201907575T4 (tr) Hayvan parazitlerini kontrol etmeye yönelik faydalı ajanlar olarak aminobenzamid türevleri.
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2010078324A3 (en) Companion animal compositions including lipoic acid and methods of use thereof
IN2012DN01453A (zh)
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
WO2009087632A3 (en) Emulsified wax compositions and uses thereof
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2008107092A3 (en) Use of derivatives of 4-hydroxyphenoxy acetic acid
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2008135661A3 (fr) Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
WO2010031248A8 (zh) 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
EP2801359A3 (en) The use of nicotine for the treatment of sepsis in humans caused by antibiotic
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09813969

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2011527183

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13120009

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009813969

Country of ref document: EP